ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Ludwig, H., Durie, S. N., Meckl, A., Hinke, A. & Durie, B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncol. 25, e1406–e1413 (2020).

doi: 10.1634/theoncologist.2020-0141

Pillarisetti, K. et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 4, 4538–4549 (2020).

pubmed: 32956453 pmcid: 7509877 doi: 10.1182/bloodadvances.2020002393

Usmani, S. Z. et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 7, e447–e455 (2020).

pubmed: 32470437 doi: 10.1016/S2352-3026(20)30081-8

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

pubmed: 33626253 doi: 10.1056/NEJMoa2024850

Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).

pubmed: 35661166 pmcid: 10587778 doi: 10.1056/NEJMoa2203478

Seckinger, A. et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31, 396–410 (2017).

pubmed: 28262554 doi: 10.1016/j.ccell.2017.02.002

Wong, S. W. et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood 140, 400–402 (2022).

doi: 10.1182/blood-2022-159009

Larrea et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146–154 (2020).

doi: 10.1158/2643-3230.BCD-20-0020

van de Donk, N. W. C. J., O’Neill, C., de Ruijter, M. E. M., Verkleij, C. P. M. & Zweegman, S. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr. Opin. Oncol. 35, 601–611 (2023).

pubmed: 37501530 pmcid: 10566598 doi: 10.1097/CCO.0000000000000983

Skegro, D. et al. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J. Biol. Chem. 292, 9745–9759 (2017).

pubmed: 28450393 pmcid: 5465497 doi: 10.1074/jbc.M117.782433

Stutz, C. & Blein, S. A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species. J. Biol. Chem. 295, 9392–9408 (2020).

pubmed: 32404368 pmcid: 7363136 doi: 10.1074/jbc.RA119.012335

North, B., Kocher, H. M. & Sasieni, P. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer 19, 632 (2019).

pubmed: 31242873 pmcid: 6595589 doi: 10.1186/s12885-019-5801-3

US FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. https://www.fda.gov/media/72309/download (2005).

European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf (2018).

Lund, J. et al. Multiple binding sites on the CH2 domain of IgG for mouse FcγR11. Mol. Immunol. 29, 53–59 (1992).

pubmed: 1530984 doi: 10.1016/0161-5890(92)90156-R

Idusogie, E. E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178–4184 (2000).

pubmed: 10754313 doi: 10.4049/jimmunol.164.8.4178

Funaro, A. & Malavasi, F. Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. J. Biol. Regul. Homeost. Agents 13, 54–61 (1999).

pubmed: 10432444

Ferrero, E. & Malavasi, F. The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. J. Leukoc. Biol. 65, 151–161 (1999).

pubmed: 10088597 doi: 10.1002/jlb.65.2.151

Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019).

pubmed: 30896447 pmcid: 6546468 doi: 10.1172/JCI126397

Perro, M., Iannacone, M., von Andrian, U. H. & Peixoto, A. Role of LFA-1 integrin in the control of a lymphocytic choriomeningitis virus (LCMV) infection. Virulence 11, 1640–1655 (2020).

pubmed: 33251934 pmcid: 7714442 doi: 10.1080/21505594.2020.1845506

Cremasco, F. et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS ONE 16, e0241091 (2021).

pubmed: 33406104 pmcid: 7787458 doi: 10.1371/journal.pone.0241091

Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148–3157 (2020).

doi: 10.1182/blood-2003-06-1984

Zafra et al. Targeting multiple myeloma with AMG 424, a novel Anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921–3933 (2019).

doi: 10.1158/1078-0432.CCR-18-2752

Kim, K. & Phelps, M. A. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin. Pharmacokinet. 62, 789–806 (2023).

pubmed: 37129750 pmcid: 10760401 doi: 10.1007/s40262-023-01240-8

Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711–725.e6 (2023).

pubmed: 36898378 doi: 10.1016/j.ccell.2023.02.008

Rodriguez-Otero, P. et al. Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a phase 1b multicohort study. Blood 138, 1647–1647 (2021).

doi: 10.1182/blood-2021-148723

Betts, A. et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART®. AAPS J. 21, 66 (2019).

pubmed: 31119428 doi: 10.1208/s12248-019-0332-z

Zhao, J., Cao, Y. & Jusko, W. J. Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model. Pharm. Res. 32, 3269–3281 (2015).

pubmed: 25939552 pmcid: 4580522 doi: 10.1007/s11095-015-1703-5

Betts, A. & van der Graaf, P. H. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin. Pharmacol. Ther. 108, 528–541 (2020).

pubmed: 32579234 pmcid: 7484986 doi: 10.1002/cpt.1961

Ball, K., Dovedi, S. J., Vajjah, P. & Phipps, A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 15, 2181016 (2023).

pubmed: 36823042 pmcid: 9980545 doi: 10.1080/19420862.2023.2181016

Abrams, R. E. et al. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma. Sci. Rep. 12, 10976 (2022).

pubmed: 35768621 pmcid: 9243109 doi: 10.1038/s41598-022-14726-5

Qi, T., Liao, X. & Cao, Y. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends Pharmacol. Sci. 44, 880–890 (2023).

pubmed: 37852906 doi: 10.1016/j.tips.2023.09.009

Yuan, D., Rode, F. & Cao, Y. A minimal physiologically based pharmacokinetic model with a nested endosome compartment for novel engineered antibodies. AAPS J. 20, 48 (2018).

pubmed: 29541870 doi: 10.1208/s12248-017-0183-4

Germovsek, E., Cheng, M. & Giragossian, C. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. mAbs 13, 1964935 (2021).

pubmed: 34530672 pmcid: 8463036 doi: 10.1080/19420862.2021.1964935

US FDA. NDA/BLA Multi-disciplinary Review and Evaluation. 761291Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761291Orig1s000MultidisciplineR.pdf (2022).

Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398, 665–674 (2021).

pubmed: 34388396 doi: 10.1016/S0140-6736(21)01338-6

Suh, H. Y., Peck, C. C., Yu, K.-S. & Lee, H. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des. Dev. Ther. 10, 4005–4016 (2016).

doi: 10.2147/DDDT.S121520

Saber, H., Valle, P. D., Ricks, T. K. & Leighton, J. K. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul. Toxicol. Pharm. 90, 144–152 (2017).

doi: 10.1016/j.yrtph.2017.09.001

Lesokhin A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. https://doi.org/10.1038/s41591-023-02528-9 (2023).

Cappell, K. M. et al. Long-Term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805–3815 (2020). Jco2001467.

pubmed: 33021872 pmcid: 7655016 doi: 10.1200/JCO.20.01467

Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988–5999 (2020).

pubmed: 33284948 pmcid: 7724898 doi: 10.1182/bloodadvances.2020002827

San-Miguel, J. et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 139, 492–501 (2021).

doi: 10.1182/blood.2020010439

Martin, T. et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265–1274 (2023).

pubmed: 35658469 doi: 10.1200/JCO.22.00842

Zhao, B. et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J. Hematol. Oncol. 15, 153 (2022).

pubmed: 36284349 pmcid: 9597993 doi: 10.1186/s13045-022-01364-7

Zhou, X. et al. High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Haematologica 108, 1628–1639 (2023).

pubmed: 36727403 pmcid: 10230416 doi: 10.3324/haematol.2022.282225

Saltarella, I. et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells 9, 167 (2020).

pubmed: 31936617 pmcid: 7017193 doi: 10.3390/cells9010167

van de Donk, N. W. C. J. & Usmani, S. Z. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 (2018).

pubmed: 30294326 pmcid: 6158369 doi: 10.3389/fimmu.2018.02134

Nijhof et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128, 959–970 (2016).

pubmed: 27307294 doi: 10.1182/blood-2016-03-703439

Brudno, J. N. et al. T cells genetically modified to express an anti-b-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267–2280 (2018).

pubmed: 29812997 pmcid: 6067798 doi: 10.1200/JCO.2018.77.8084

Green, D. J. et al. Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood 132, 1011–1011 (2018).

doi: 10.1182/blood-2018-99-117729

Feng, Y. et al. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. OncoImmunology 10, 1959102 (2021).

pubmed: 34434610 pmcid: 8381848 doi: 10.1080/2162402X.2021.1959102

Chen, H. et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk. Res. 81, 62–66 (2019).

pubmed: 31035033 doi: 10.1016/j.leukres.2019.04.008

Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016).

pubmed: 27412889 pmcid: 5043125 doi: 10.1182/blood-2016-04-711903

Truger, M. S. et al. Single and double hit events in genes encoding for immune targets before and after T cell engaging antibody therapy in MM. Blood Adv. 5, 3794–3798 (2021).

pubmed: 34471932 pmcid: 8679680 doi: 10.1182/bloodadvances.2021004418

Vià, M. C. D. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616–619 (2021).

pubmed: 33619368 doi: 10.1038/s41591-021-01245-5

Pilcher, W. et al. Characterization of T-cell exhaustion in rapid progressing multiple myeloma using cross center scRNA-seq study. Blood 138, 401–401 (2021).

doi: 10.1182/blood-2021-153863

Karki, R. & Kanneganti, T.-D. The ‘cytokine storm’: molecular mechanisms and therapeutic prospects. Trends Immunol. 42, 681–705 (2021).

pubmed: 34217595 pmcid: 9310545 doi: 10.1016/j.it.2021.06.001

Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).

pubmed: 30592986 doi: 10.1016/j.bbmt.2018.12.758

Valitutti, S., Müller, S., Dessing, M. & Lanzavecchia, A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183, 1917–1921 (1996).

pubmed: 8666949 doi: 10.1084/jem.183.4.1917

Labrijn, A. F. et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat. Protoc. 9, 2450–2463 (2014).

pubmed: 25255089 doi: 10.1038/nprot.2014.169

Benaniba, L. et al. The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 19, 855 (2019).

pubmed: 31464608 pmcid: 6714387 doi: 10.1186/s12885-019-6080-8

Ghose, J. et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology 7, e1486948 (2018).

pubmed: 30288349 pmcid: 6169590 doi: 10.1080/2162402X.2018.1486948

Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911–922 (2016).

pubmed: 27313079 doi: 10.1111/bjh.14145

Press, O. W., Hansen, J. A., Farr, A. & Martin, P. J. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res. 48, 2249–2257 (1988).

pubmed: 2964899

Lee, J. Y., Ryu, H. S., Yoon, S. S., Kim, E. H. & Yoon, S. W. Extracellular-to-intracellular fluid volume ratio as a prognostic factor for survival in patients with metastatic cancer. Integr. Cancer Ther. 18, 1534735419847285 (2019).

pubmed: 31043080 pmcid: 6498769 doi: 10.1177/1534735419847285

Hassan, H. T. & El-Sheemy, M. Adult bone-marrow stem cells and their potential in medicine. JRSM 97, 465–471 (2004).

pubmed: 15459256 pmcid: 1079613 doi: 10.1177/0141076809701003

Cao, Y. & Jusko, W. J. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J. Pharmacokinet. Pharmacodyn. 41, 375–387 (2014).

pubmed: 25077917 pmcid: 4167346 doi: 10.1007/s10928-014-9372-2

Cao, Y., Balthasar, J. P. & Jusko, W. J. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J. Pharmacokinet. Pharmacodyn. 40, 597–607 (2013).

pubmed: 23996115 doi: 10.1007/s10928-013-9332-2

Betts, A. M. et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Ther. 333, 2–13 (2010).

pubmed: 20089807 doi: 10.1124/jpet.109.164129

Bisset, L. R., Lung, T. L., Kaelin, M., Ludwig, E. & Dubs, R. W. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur. J. Haematol. 72, 203–212 (2004).

pubmed: 14962239 doi: 10.1046/j.0902-4441.2003.00199.x

STEMCELL Technologies. Frequencies of Cell Types in Human Peripheral Blood. https://www.stemcell.com/media/files/wallchart/10000015062-Frequencies_of_Human_Cell_Types_in_Blood_Related_Sources.pdf (2019).

Granell, M. et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 102, 1099–1104 (2017).

pubmed: 28255016 pmcid: 5451342 doi: 10.3324/haematol.2016.158303

Prokopishyn, N. L. et al. The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time. Biol. Blood Marrow Transplant. 25, 1325–1330 (2019).

pubmed: 30716454 pmcid: 6615955 doi: 10.1016/j.bbmt.2019.01.034

Rosa, F. D. & Gebhardt, T. Bone marrow T cells and the integrated functions of recirculating and tissue-resident memory T cells. Front. Immunol. 7, 51 (2016).

pubmed: 26909081 pmcid: 4754413

Canadian Cancer Society. What is Multiple Myeloma? https://cancer.ca/en/cancer-information/cancer-types/multiple-myeloma/what-is-multiple-myeloma (2024).

Moreno, L. et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin. Cancer Res. 25, 3176–3187 (2019).

pubmed: 30692097 doi: 10.1158/1078-0432.CCR-18-1597

Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191 (2007).

pubmed: 17695343 doi: 10.3758/BF03193146

Multiple Myeloma Research Foundation. Understanding Multiple Myeloma. https://themmrf.org/multiple-myeloma (2024).

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Classifications MeSH